La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Novozymes Gestione

Gestione criteri di controllo 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Ester Baiget

Amministratore delegato

DKK 29.1m

Compenso totale

Percentuale dello stipendio del CEO	33.3%
Mandato del CEO	4.2yrs
Proprietà del CEO	n/a
Durata media del management	1.7yrs
Durata media del Consiglio di amministrazione	3.6yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Ester Baiget rispetto agli utili di Novozymes?
Data	Compenso totale	Stipendio	Guadagni aziendali
Dec 31 2023	DKK 29m	DKK 10m	DKK 3b
Sep 30 2023	n/a	n/a	DKK 3b
Jun 30 2023	n/a	n/a	DKK 3b
Mar 31 2023	n/a	n/a	DKK 4b
Dec 31 2022	DKK 24m	DKK 10m	DKK 4b
Sep 30 2022	n/a	n/a	DKK 3b
Jun 30 2022	n/a	n/a	DKK 3b
Mar 31 2022	n/a	n/a	DKK 3b
Dec 31 2021	DKK 24m	DKK 8m	DKK 3b
Sep 30 2021	n/a	n/a	DKK 3b
Jun 30 2021	n/a	n/a	DKK 3b
Mar 31 2021	n/a	n/a	DKK 3b
Dec 31 2020	DKK 24m	DKK 7m	DKK 3b

Compensazione vs Mercato: La retribuzione totale di Ester ($USD 4.24M ) è circa la media per le aziende di dimensioni simili nel mercato MX ($USD 6.09M ).

Compensazione vs guadagni: La retribuzione di Ester è aumentata di oltre il 20%, mentre gli utili aziendali sono diminuiti di oltre il 20% nell'ultimo anno.

AMMINISTRATORE DELEGATO

Ester Baiget (52 yo)

4.2yrs

Mandato

DKK 29,100,000

Compensazione

Ms. Ester Baiget serves as Chief Executive Officer and President of Novozymes A/S since joining on February 1, 2020. She serves as Member of Supervisory Board at Akzo Nobel N.V. since 2022. She served as t...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Ester Baiget	President & CEO	4.2yrs	DKK 29.10m	Nessun dato
Rainer Lehmann	Executive VP & CFO	less than a year	DKK 6.40m	Nessun dato
Anders Lund	Chief Operating Officer	less than a year	DKK 7.70m	Nessun dato
Claus Fuglsang	Chief Scientific Officer	3.6yrs	Nessun dato	Nessun dato
Tobias Bjorklund	Head of Investor Relations	no data	Nessun dato	Nessun dato
Winnie Bugel	General Counsel of Legal	less than a year	Nessun dato	Nessun dato
Tue Micheelsen	Vice President of Global Sales & Marketing	no data	Nessun dato	Nessun dato
Morten Rasmussen	Executive Vice President of People & Stakeholder Relations	3yrs	Nessun dato	Nessun dato
Tina Fano	Executive Vice President of Planetary Health Biosolutions	8.2yrs	DKK 7.60m	Nessun dato
Amy Byrick	Executive Vice President of Human Health Biosolutions	3yrs	Nessun dato	Nessun dato
Henrik Nielsen	Executive Vice President of Strategy & Integration	less than a year	Nessun dato	Nessun dato
Jacob Paulsen	Executive Vice President of Food & Beverage Biosolutions	less than a year	Nessun dato	Nessun dato

1.7yrs

Durata media

49.5yo

Età media

Gestione esperta: Il team dirigenziale di NSIS N non è considerato esperto (durata media 1.7 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Jesper Brandgaard	Vice Chair of the Board	less than a year	Nessun dato	Nessun dato
Cornelis de Jong	Independent Chairman	4.2yrs	DKK 1.78m	0.0011% DKK 4.5m
Kim Stratton	Independent Vice Chair	7.2yrs	DKK 1.29m	Nessun dato
Kasim Kutay	Director	7.2yrs	DKK 803.00k	0.00023% DKK 965.4k
Heine Dalsgaard	Director	4.2yrs	DKK 1.07m	0.00065% DKK 2.7m
Lise Kaae	Director	less than a year	Nessun dato	Nessun dato
Anders Knudsen	Employee Representative Director	11.2yrs	DKK 535.00k	Nessun dato
Sharon James	Independent Director	4.2yrs	DKK 1.07m	Nessun dato
Anne Breum	Employee Representative Director	3.1yrs	DKK 535.00k	0.00010% DKK 419.7k
Preben Nielsen	Employee Representative Director	3.1yrs	DKK 803.00k	0.000090% DKK 377.8k
Jens Obro	Employee Representative Director	3.1yrs	DKK 535.00k	0.00012% DKK 503.7k
Morten Otto Sommer	Independent Director	2.1yrs	DKK 1.03m	0.00022% DKK 923.4k

3.6yrs

Durata media

59yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di NSIS N sono considerati esperti (durata media dell'incarico 3.6 anni).

Novozymes Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Novozymes A/S Announces Board Appointments

Less than half of directors are independent

Less than half of directors are independent

Novozymes A/S and Chr. Hansen Announce Executive Leadership Team and Organizational Structure

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Novonesis Approves Interim Dividend for 2024, Payable on September 3, 2024

Novonesis Provides Sales Guidance for the Year 2024

Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023

Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023

Novonesis Provides Earnings Guidance for the Year 2024

Novonesis to Unveil Fit-for-Food Mood-Support Probiotic at Natural Product Expo West

Novozymes A/S Announces Board Appointments

Novozymes A/S to Report First Half, 2024 Results on Aug 28, 2024

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Less than half of directors are independent

Novozymes A/S to Report Fiscal Year 2023 Final Results on Apr 08, 2024

Novozymes Launches Quara(R) Lowp for Renewable Diesel Feedstock Pre-T Treatment

Investor sentiment improves as stock rises 18%

Less than half of directors are independent

Novozymes Launches ProSilience™ HU58

Novozymes A/S Approves Interim Dividend, Payable on October 17, 2023

Novozymes A/S and Chr. Hansen Announce Executive Leadership Team and Organizational Structure

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Novozymes A/S Announces Change to the Executive Leadership Team

First quarter 2023 earnings released: EPS: kr.2.83 (vs kr.3.00 in 1Q 2022)

Less than half of directors are independent

Investor sentiment deteriorates as stock falls 17%

Less than half of directors are independent

Novozymes A/S Provides Earnings Guidance for the Year 2023

Novozymes A/S Announces Jørgen Buhl Rasmussen Decides Not to Seek Re-Election as Member of its Board of Directors

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Less than half of directors are independent

Third quarter 2022 earnings released

Novozymes A/S Provides Earnings Guidance for the Year 2022

Biotalys Nv and Novozymes A/S Announces Successful Evoca™ Feasibility Study

Less than half of directors are independent

Novozymes A/S to Report Q3, 2022 Results on Nov 03, 2022

Less than half of directors are independent

Second quarter 2022 earnings released: EPS: kr.2.92 (vs kr.2.85 in 2Q 2021)

Less than half of directors are independent

Novozymes A/S Provides Earnings Guidance for the Year 2022

Novozymes A/S to Report Nine Months, 2023 Results on Oct 26, 2023

Novozymes Extends the Lifetime of Textiles with Sustainable Innovation

Less than half of directors are independent

First quarter 2022 earnings released: EPS: kr.3.00 (vs kr.3.17 in 1Q 2021)

Less than half of directors are independent

Novozymes A/S Raises Full-Year Financial Guidance for 2022

Less than half of directors are independent

Upcoming dividend of kr.5.50 per share

Less than half of directors are independent

Less than half of directors are independent

Novozymes A/S Provides Revenue Guidance for 2022

Less than half of directors are independent

Novozymes A/S (CPSE:NZYM B) completed the acquisition of a 60% stake in Synergia Life Sciences Pvt. Ltd. for DKK 1 billion.

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Novozymes A/S Provides Earnings Guidance for the Full Year 2021

First quarter 2021 earnings released: EPS kr.3.17 (vs kr.2.89 in 1Q 2020)

Novozymes A/S Reaffirms Sales Guidance for the Year 2021

Univar Solutions and Novozymes® Partner to Bring Innovative, Sustainable Biotechnology Products to Customers in the United States and Canada

Novozymes Acquires Data Science Platform of Biota to Strengthen Microbiome R&D Capabilities in Probiotic Development

Novozymes A/S (CPSE:NZYM B) acquired the Microbiome R&D Team and Data Science Platform from Biota Technology, Inc.

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente